Pharma BD Deal Intelligence
A near-zero-value JV buyout that consolidated control of a platform BI later grew into a top-10 global animal health business — but the 2004 transaction itself has no isolable financial return
Full analysis, sources & comparables →Boehringer Ingelheim Animal Health Japan Co., Ltd. — the Japan animal health entity that succeeded the post-2004 BI Vetmedica Japan operation following the…
In 2004, Boehringer announced the acquisition of the outstanding shares of Boehringer Ingelheim Shionogi Vetmedica.
Source summaries from our enrichment pipeline; follow links for originals.
All 4 sources with sentiment breakdown →
December 2004 announcement; acquired outstanding minority shares; animal health globalization
A near-zero-value JV buyout that consolidated control of a platform BI later grew into a top-10 global animal health business — but the 2004 transaction itself has no isolable financial return
Assessment window: 15yr post-close.
Japan's animal health market in 2004 was the second-largest in Asia, anchored by livestock (swine, cattle, poultry), companion-animal pharmaceuticals, and aquaculture — a structurally different mix than the US/EU companion-animal-skewed markets. Boehringer Ingelheim's animal health division traced to its 1955 acquisition of Pfizer's veterinary programme; in Japan it operated through the Boehringer Ingelheim Shionogi Vetmedica joint venture with Shionogi & Co.
In December 2004 Boehringer Ingelheim announced the acquisition of the outstanding shares of Boehringer Ingelheim Shionogi Vetmedica, consolidating the Japan animal health JV as a wholly-owned BI subsidiary [en.wikipedia.org/wiki/Boehringer_Ingelheim]. Shionogi exited animal health to refocus on its core human prescription pharmaceutical franchises. Competing animal health players in Japan in 2004 included Sanofi's Merial, Pfizer Animal Health (which BI's US subsidiary later acquired Fort Dodge from in 2009), Bayer Animal Health, Intervet (Schering-Plough), and Meiji Seika's veterinary unit. Forward-looking: BI Japan's animal health platform expanded materially over the next 15 years — first by absorbing Fort Dodge assets in 2009, then by the transformative June 2016 asset swap with Sanofi that valued Merial at €11.4 billion / $12.4 billion and made Boehringer Ingelheim Animal Health the world's #2 animal health company; the consolidated Japan operation now trades as Boehringer Ingelheim Animal Health Japan Co., Ltd. [en.wikipedia.org/wiki/Boehringer_Ingelheim].
| Deal | Year | Value | Outcome |
|---|---|---|---|
| Boehringer Ingelheim / Boehringer Ingelheim Shionogi Vetmedica (Shionogi stake) (this deal) | 2004 | — | 52 |
| Boehringer Ingelheim / Brainomix | 2024 | — | — |
| Boehringer Ingelheim / Mary Tyler Moore Vision Initiative | 2024 | — | — |
| Boehringer Ingelheim / ViVerita Therapeutics | 2025 | — | — |
| Boehringer Ingelheim / Variant Bio | 2026 | — | — |
| Boehringer Ingelheim / Re-Vana Therapeutics | 2025 | — | — |
| Boehringer Ingelheim / Jazz Pharmaceuticals | 2026 | — | — |
← Browse all deals · How we score deals
More: 2004 deals · Boehringer Ingelheim deals